🔗 Share this article

A shadow market for unapproved weight-loss medications is being driven by social media fitness personalities and vendors on communication apps, according to recent findings.

Experimental Drug Acquiring Traction Via Social Media

The experimental drug, which remains in clinical trials, is being advertised by social media influencers for its alleged weight-reducing properties. Followers are encouraged to contact these profiles privately for source information, while also receiving promotional offers.

Active Trade on Social Networks

Additionally, a robust market exists on messaging services, where communities with thousands of members share “before and after” images, administration instructions and assertions of rapid British shipping. Vendors promote the substance there before directing customers to WhatsApp for purchases.

Understanding The Experimental Drug

Retatrutide is an experimental injection created by American pharmaceutical company Eli Lilly. The treatment affects three intestinal hormones – GLP-1, glucose-dependent insulinotropic polypeptide and pancreatic hormone. Preliminary studies indicate it could assist individuals reduce up to a quarter of their total weight. Nicknamed the “triple G”, the drug is being hailed online as the next Ozempic.

Healthcare Professionals Express Concerns

However, physicians and chemists have cautions that the distribution of what is still an unapproved drug in the United Kingdom is a cause for concern and could result in users injecting substances of unknown origin.

Some professionals said the demand for the experimental drug could be connected to the increasing price of licensed slimming treatments such as Mounjaro.

Legal Status and Implementation

Selling the unapproved drug on TikTok or messaging apps is prohibited in the UK, as it is an unlicensed medication that must not be promoted or distributed for personal consumption under the British medical regulations.

Some content creators try to sidestep the regulations by referring to the drug as a “research chemical” or describing it as “not for human consumption”. The substance is not a controlled drug, but advertising and supply can still breach pharmaceutical, marketing, and consumer laws, potentially leading to penalties, legal action or prison.

Service Response and Content Removal

According to the social media company, the platform has taken down violative content and prohibited related keywords and search suggestions. The organization said it was committed to maintaining the service secure and allocating resources in strengthening enforcement strategies.

Online Marketplace Activities

Research also found groups with up to nine thousand participants marketing the experimental drug using the platform's integrated discovery tool, which operates like a online catalog. Entering “retatrutide” instantly displays groups with numerous of members, populated with images of weight loss, glowing reviews and detailed instructions for preparing or administering at residence.

Within minutes of joining one community, a seller posted WhatsApp details, where the majority of transactions occur. The seller provided an instruction manual and guaranteed shipping within two days. When questioned whether the substance was genuine, one vendor said: “You can’t be sure.” Another shared a image of a supposed laboratory certificate. Not one asked about body mass, health issues or previous experience.

Product Information and Pricing

Within these groups, messages display black plastic parcels with Royal Mail labels, claiming to include fresh supplies. One message stated: “It took eight of us to load them this morning.”

Customers can select between powder vials, prepared at home with purified liquid, or ready-to-use injectors usually priced at £160 for 20 milligrams. When asked how long a injector should be used, vendors give contradictory answers ranging from a several days to “depends on your body”.

Service Moderation and Safety Actions

A spokesperson for the messaging service said it regularly monitored harmful material on its platform including material that promoted the “misuse of controlled medications”. The company noted that it eliminated “millions of pieces of harmful content each day”.

Healthcare Expert Warnings

“Individuals are injecting substances they can’t verify. Even if the science behind this drug is valid, these digital versions may not include what they claim,” stated Jason Murphy, the director of pharmaceutical services at a pharmacy service.

Dr Crystal Wyllie of Asda Online Doctor linked the surge in interest to current price rises for approved slimming drugs such as Mounjaro. “With prices increasing, patients are using social media. But fake injections are highly dangerous. You cannot know what’s inside or whether the conditions they were produced in was clean,” she said.

Her team has previously seen patients harmed by personal administration from unverified sources. “We recognize the disappointment, but purchasing from messaging apps or communication platforms is gambling with your well-being,” stated the doctor. “These substances could be impure or improperly measured.”

Manufacturer Position

A spokesperson from the pharmaceutical company stated the substance was in phase 3 clinical trials and had not been reviewed or authorized by any regulatory agency anywhere in the world. “Consequently at this time no one can sell [it] for personal consumption,” they explained, noting that any product “falsely representing itself as a Lilly investigational product not yet authorized … may subject patients to possibly serious medical dangers”.